Company news
BioXcel Therapeutics, Inc. news in 2020
BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
December 6, 2020
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 11, 2020
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
November 10, 2020
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium
October 25, 2020
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 13, 2020
BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
July 19, 2020
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from Delirium and Agitation
July 8, 2020
BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation
July 6, 2020
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer
June 22, 2020
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer
June 15, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms
June 10, 2020
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501
May 13, 2020
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 11, 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer
April 27, 2020
BioXcel Therapeutics Provides an Update on its Ongoing Phase 3 SERENITY Trials
March 18, 2020
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 8, 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
February 17, 2020
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
February 4, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia
January 6, 2020
Decks in 2020
- Investor Presentation (April 2020)
Investor deck · 30 slides · Apr 15, 2020